The second study reference yesterday:

A recent study (S Hanauer et al. Clin Gastroenterol Hepatol 2019; 17: 139-47) shows that tofacitinib can work quickly to reduce symptoms in ulcerative colitis.

In a post-hoc analyses of data from OCTAVE induction 1 and 2 (n=905 patients, n=234 placebo), the authors determined that tofacitinib reduces symptoms within 3 days.

Key findings:

• By day 3, there was a reduction in stool frequency (-1.06 vs. -0.27 for placebo) and a reduction in rectal bleeding subscore (-0.30 vs -0.14 for placebo)
• 28.8% of tofacitinib-treated patients had a reduction in stool frequency subscore by >1 point compared to 17.9% for placebo.  For rectal bleeding subscore, tofacitinib-treated patients had a reduction by >1 point in 32% compared to 17.9% for placebo 20.1%.

My take: This study reinforces the impression that tofacitinib works rapidly.

Related blog posts:

• Tofacitinib for Induction and Maintenance of Ulcerative Colitis
• AGA Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis
• Management of Acute Severe Colitis | gutsandgrowth
• Latest on Tofacitinib for Refractory Ulcerative Colitis
• Tofacitinib –a JAK Inhibitor for UC
• Tofacitinib -Risks and Benefits in Rheumatoid Arthritis

La Boqueria, Barcelona